March 16th 2024
A phase 2 trial showed favorable antitumor activity when tislelizumab plus chemotherapy was used for patients with locally advaned cervical cancer.
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Moderate-Dose External Radiation Plus Implants Increase Survival in Cervical Cancer
July 1st 1999Standard radiation therapy for patients with latestage cervical cancer (stage IIIB) should be adjusted so that each patient receives moderate doses of external-beam radiation therapy plus radioactive implants, according to a study led by Dr. Mark
Church-Based Project Provides Cervical Cancer Screening for Latinas
June 1st 1999SAN FRANCISCO-A single-visit cervical cancer screening program conducted before and after church services may help extend the benefits of early diagnosis and treatment to underserved populations, according to research presented at the 30th annual meeting of the Society of Gynecologic Oncologists.
Chemo Improves Survival in High-Risk Cervical Cancer
June 1st 1999SAN FRANCISCO-A major intergroup phase III study reported at the 30th Annual Meeting of the Society of Gynecologic Oncologists has shown that adding chemotherapy to radiation therapy improves the overall survival rate for women with high-risk early-stage cervical cancer. William A. Peters III, MD, of the Puget Sound Oncology Consortium, Seattle, reported the results on behalf of researchers from the Southwest Oncology Group, Gynecologic Oncology Group, and Radiation Therapy Oncology Group.
Chemotherapy Plus Radiation Improves Survival in Patients With Cervical Cancer
March 1st 1999The National Cancer Institute (NCI) recently sent a clinical announcement to thousands of physicians stating that strong consideration should be given to adding chemotherapy to radiation therapy in the treatment of invasive cervical cancer.
NCI Plans Major Efficacy Trial of HPV Vaccine in Costa Rica
January 1st 1999BETHESDA, Md-Buoyed by early findings from a phase I trial, researchers at the National Cancer Institute plan to launch an efficacy trial of an NCI-developed vaccine against human papillo-mavirus-16 (HPV-16), a leading cause of cervical cancer. The study will involve 6,000 women.
Lower Genital Tract Neoplasia in Women With HIV Infection
December 1st 1998Although overall death rates from the acquired immune deficiency syndrome (AIDS) are declining rapidly, the incidence of human immunodeficiency virus (HIV) in women continues to climb, and HIV-associated gynecologic disease is also likely toincrease over the next decade. In this paper on lower genital tract neoplasia in women with HIV infection, Abercrombie and Korn review some of the many studies documenting the increased incidence of cervical human papillomavirus (HPV) and HPV-asso-ciated disease in this population. The clinical importance of these studies is underscored by recent data from New York City, where the incidence of invasive cervical cancer increased significantly from 1990 to 1995 in HIV-positive women, compared to the general popu-lation of 25- to 49-year-old women.[1]
US Clinical Trial of New Cervical Cancer Detection System to Begin
October 1st 1998NetMed, Inc., a developer and marketer of medical and health-related technologies, announced the commencement of a multicenter US clinical trial of the PAPNET cervical cancer detection system as a primary screening test for Pap smears. The
Genetic Markers May Predict Risk for Lung, Prostate, Colorectal, and Cervical Cancers
June 1st 1998Recent advances in research focused on identifying genetic and other markers that can predict cancer risk were reported at the annual meeting of the American Association for Cancer Research (AACR). Included in the presentations were reports of
FDA Approves NeoPath’s AutoPap For Primary Pap Smear Screening
June 1st 1998ROCKVILLE, Md--The FDA has approved NeoPath, Inc.’s AutoPap System, an automated diagnostic system for detection of cervical cancer, for use as a primary Pap smear screen. In a prospective, intended use clinical study comprised of more than 25,000 patient slides from five clinical laboratories, AutoPap achieved greater overall accuracy in the early diagnosis of cervical disease than current practice and reduced both false-negative and false-positive test results.
Practice Guidelines: Vulvar Cancer
February 1st 1998Malignant diseases of the vulva account for an estimated 3% to 5% of gynecologic neoplasia. The pathologic variants are many (Table 1). Squamous cell cancers account for 85% to 90% of these neoplasms. Melanoma, Bartholin gland cancer, Paget’s disease, and the various sarcomas are the other principal neoplasms. The preinvasive forms of the squamous cancer tend to occur in younger women and may be associated with in situ lesions of the cervix, vagina, perineum, and anus.
Practice Guidelines: Uterine Corpus—Endometrial Cancer
January 1st 1998Endometrial cancer is the most common type of female genital cancer in the United States, with an estimated 32,000 new cases and 5,600 deaths per year. During the first half of the 20th century, the incidence of cervical cancer was greater than
Researchers Report Conflicting Data on Cervical Cancer in AIDS
July 1st 1997BETHESDA, Md--A review of 10 years' experience with HIV-infected patients treated at University Hospital, Newark, NJ, revealed significantly elevated levels of several types of cancers, but a surprising dearth of invasive cervical cancers, which prompted the study's lead author to suggest dropping cervical cancer from the list of AIDS-associated malignancies.
Summary of the NIH Consensus Development Conference on Cervical Cancer
May 1st 1997Carcinoma of the cervix is one of the most common malignancies in women, accounting for 15,700 new cases and 4,900 deaths in the United States each year. Worldwide, cervical cancer is second only to breast cancer as the most common
Radiation Therapy for Malignancies in the Setting of HIV Disease
May 1st 1997With the introduction of increasingly effective antiretroviral agents for the management of AIDS, the life expectancy of appropriately treated patients will continue to lengthen, as will the length of time during which infected patients may develop malignancies, both HIV-related and non-HIV-related. The management of such patients will require careful consideration of the impact of all oncologic therapy on the immune system's ability to hold the virus at bay. Radiation therapy, with its recognized immunosuppressive effects, plays an important role in the management of the major AIDS-defining neoplasms, Kaposi's sarcoma, primary central nervous system lymphoma, and cervical carcinoma, and is used in approximately 50% of patients with non-HIV-related malignancies at some point in the disease course. The judicious use of radiation therapy and proper integration of aggressive antiretroviral therapy can result in control of malignancies without contributing to the rapid progression of HIV disease. [ONCOLOGY 11(5):683-694, 1997]
Myoepithelial Cells May Be Key to Suppression of DCIS Growth
April 1st 1997LOS ANGELES--Laboratory studies from the UCLA School of Medicine point to a role for myoepithelial cells in suppressing breast cancer invasion, said researcher Mark Sternlicht, PhD. Myo-epithelial cells lie between the epithelium and the basement membrane. They synthesize and maintain the basement membrane and can promote epithelial differentiation. They are found surrounding benign and nonmalignant lesions.
Extent of Genital Infection With Cancer-Linked HPV May Relate to the Type of Immune Response
March 1st 1997A study of women with cervical intraepithelial neoplasia (CIN), a condition that often precedes invasive cervical cancer and is linked to infection with certain strains of human papillomavirus (HPV), found that those with the most extensive infections also
'More May Be Less' in Metastatic Cervical Cancer
February 1st 1997VIENNA--A new study from the EORTC Gynecologic Cancer Cooperative Group (GCCG) has challenged the assumption that aggressive combination chemotherapy is worthwhile in chemotherapy-naïve women with metastatic squamous cell cancer of the cervix.